概括
这项研究发现,皮并没有改善社区获得的严重肺炎患者的治疗结果. 在这种患者群体中,皮质类固醇治疗没有降低死亡率或其他关键临床终点.
科学领域:
- 关键护理医学 关键护理医学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 严重的社区性肺炎 (SCAP) 是死亡的一个重要原因.
- 皮质类固醇在治疗SCAP中的作用仍然存在争议.
- 现有的指导方针提供了关于SCAP中皮质类固醇使用的各种建议.
研究的目的:
- 评估在社区获得的严重肺炎患者中皮质的疗效和安全性.
- 为了确定水皮质的管理是否降低死亡率或改善SCAP的临床结果.
- 调查皮对二次感染和其他不良事件的影响.
主要方法:
- 进行了一项随机,双盲,安慰剂控制的试验.
- 患有严重社区获得性肺炎的参与者接受了静脉注射的皮或安慰剂.
- 关键结局包括28天全因死亡率,需要机械通风和休克.
主要成果:
- 在皮和安慰剂组之间没有观察到28天死亡率的显著差异.
- 皮治疗并没有减少对机械通风或血管压缩器的需求.
- 在两组中,二次感染和其他不良事件的发生率相似.
结论:
- 皮在降低死亡率或改善严重社区获得性肺炎患者的临床结果方面无效.
- 皮质类固醇治疗不应常规推用于SCAP.
- 可能需要进一步的研究来确定可能受益于皮的特定子组.
相关概念视频
Pneumonia IV: Management
338
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
338
COPD: Management Using Bronchodilators and Corticosteroids
217
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
217
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
273
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
273
Acute Respiratory Failure-IV
160
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
160
Acute Respiratory Failure-II
249
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
249
Pneumonia III: Complications and Assessment
242
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
242


